Management of Oral Toxcities associated with GPRC5D Bispecifics Nail
Experts discuss the adverse events observed with talquetamab, including oral toxicities and skin and nail issues, and how these are managed.
EP: 1.Overview of Relapsed/Refractory Multiple Myeloma: Diagnosis, Treatment Options, Unmeet Needs
EP: 2.MonumenTAL-1: Long Term Follow up Efficacy
EP: 3.MonumenTAL-1: Safety and AEs
EP: 4.Managing GPRC5D Therapy: Unique AE Challenges and Patient Preparation
EP: 5.Administering GPRC5D therapy: Dosing and Monitoring for CRS & ICANS
EP: 6.Managing toxicities of BCMA_targeting Bispecfics
Now Viewing
EP: 7.Management of Oral Toxcities associated with GPRC5D Bispecifics Nail
EP: 8.Management of Skin and Nail AEs: Advice to Patients and Caregivers
EP: 9.Prophylactic Strategies and Advice for Managing AEs in Bispecific Therapies
EP: 10.Unmet Needs and Future Perspectives on the treatment of R/R MM
Video content above is prompted by the following:
What are some adverse events (AEs) observed with talquetamab and how are these managed?
- Please discuss management of oral toxicities.
- Please discuss management of skin and nail AEs.
Recent Videos
Related Content
